We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » COURT OVERTURNS FDA DECISION, GIVES APOTEX PAXIL EXCLUSIVITY
COURT OVERTURNS FDA DECISION, GIVES APOTEX PAXIL EXCLUSIVITY
January 13, 2004
In a ruling that could change the way the FDA grants 180-day exclusivity, a federal judge has reversed the agency’s decision that Apotex must share its six-month exclusivity period for a version of GlaxoSmithKline’s depression drug Paxil with rival generic firms.